India, July 24 -- Kenvue Inc. (KVUE) announced that the FDA has approved TYLENOL with Naproxen, the first and only over the counter fixed dose combination of acetaminophen (650 mg) and naproxen sodium (220 mg) for pain relief.
This new formulation combines the fast-acting relief of acetaminophen with the long-lasting anti-inflammatory effect of naproxen sodium, beginning to work in under 30 minutes and providing up to 12 hours of relief in a single dose. The approval addresses a critical gap in pain management, as surveys show that three out of four persistent pain sufferers are dissatisfied with current options.
The FDA decision is supported by eight clinical studies demonstrating superior pain relief compared to acetaminophen or naproxe...